Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 10, 2019 9:30 AM - Nov 12, 2019 5:40 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

DIAmond Session 1: What Do Patients Want for Clinical Trials and Clinical Research? What Should Stakeholders Do?

Session Chair(s)

Naomi  Sakurai

Naomi Sakurai


CSR-Project, NPO, Japan

Yoshikata  Furuya, MSc

Yoshikata Furuya, MSc

Manager, General Affairs Division

Sankeien Hoshoukai Foundation, Japan

Patient and Public Involvement (PPI) in drug developments is increasingly attracting interest in Japan. DIA has organized sessions on PPI at the annual meetings over the past few years to share the concept of PPI and status of PPI in each phase of drug development in Japan and global. In this DIAmond session, leaders of PPI in clinical trials and clinical research will share the latest outcomes and discuss what stakeholders should do to promote PPI in Japan.


Yasuhiro  Fujiwara, MD, PhD

Yasuhiro Fujiwara, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Chief Executive

Agnès  Saint-Raymond, DrMed

Patients’ expectations in Clinical Trials

Agnès Saint-Raymond, DrMed

European Medicines Agency, Netherlands

Head of Division International Affairs

Kyoko  Imamura, MD, PhD

Promoting Patient and Public Involvement in Japan

Kyoko Imamura, MD, PhD

Graduate School of Pharmaceutical Sciences, the University of Tokyo, Japan

Professor, Social Cooperation Program of IT Healthcare

Takayuki  Imaeda, MPharm, MS

Patient and Public Involvement (PPI) in drug developments at a pharmaceutical company’s perspective

Takayuki Imaeda, MPharm, MS

Pfizer R&D Japan, Japan

Head of Regulatory Sciences

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.